SUVEN PHARMAEarnings PresentationQ2 & H1FY21
Risk Statement
Except for historical information, all of the statements, expectations and assumptions, includingexpectations and assumptions, contained in this presentation may be forward-looking statements thatinvolve a number of risks and uncertainties. Although Suven attempts to be accurate in making theseforward-looking statements, it is possible that future circumstances might differ from the assumptionson which such statements are based. Other important factors which could cause these statements todiffer materially including outsourcing trends, economic conditions, dependence on collaborativepartnership programs, retention of key personnel, technological advances and continued success ingrowth of sales that may make our products/services offerings less competitive; Suven may notundertake to update any forward-looking statements that may be made from time to time.
2
Table of Contents
Operation & Financial
Performance Q2FY21
Company Background
144
3
Operation & Financial Performance Q2 FY21
4
Businesswise data
5
206.78
144.17
298.55
269.05
Q2FY20 Q2FY21 H1FY20 H1FY21
CDMO Pharma
Note: Figures in Rs. Crore
54.32
68.22
154.85161.73
Q2FY20 Q2FY21 H1FY20 H1FY21
CDMO Spec Chem
13.21
25
19.9
44.84
Q2FY20 Q2FY21 H1FY20 H1FY21
Formulations & Other
Services
Financial Snapshot
Growth inRevenue
Growth inEBITDA
Growth inPAT
6
Q2FY21 H1FY21
-24.50%-14.59% -20.35%
-8.12%0.73% -10.44%
Key Ratios Q2FY21 Q2FY20
EBIT toIncome
EBITDA to Income
PAT to Income
47.03%
41.58%
45.05%
38.42%
33.41%
31.16%
7
Key Ratios H1FY21 H1FY20
EBIT toIncome
EBITDA to Income
PAT to Income
49.32%
44.98%
47.01%
41.96%
38.67%
34.38%
8
Financials Q2FY21
2,784
2,440 2,377
Q2FY20 Q1FY21 Q2FY21
RUPE
ES M
N
Revenue1,309
1,178
989
Q2FY20 Q1FY21 Q2FY21
RUPE
ES M
N
EBIDTA
3.7 3.6
2.9
Q2FY20 Q1FY21 Q2FY21
RUPE
ES
EPS930 915
741
Q2FY20 Q1FY21 Q2FY21RUPE
ES M
N
PAT
9
Financials H1FY21
4,782 4,817
H1FY20 H1FY21
RUPE
ES M
N
Revenue2,358
2,167
H1FY20 H1FY21
RUPE
ES M
N
EBIDTA
7.3
6.5
H1FY20 H1FY21
RUPE
ES
EPS
1,849
1,656
H1FY20 H1FY21RUPE
ES M
N
PAT
10
Financials Q2FY21
47% 48%42%
Q2FY20 Q1FY21 Q2FY21
EBITDA Margin (%)
33%38%
31%
Q2FY20 Q1FY21 Q2FY21
PAT Margin (%)
11
Financials H1FY21
49%45%
H1FY20 H1FY21
EBITDA Margin (%)
39%34%
H1FY20 H1FY21
PAT Margin (%)
12
Financial Table – Q2 & H1FY21
30-Sep-20 30-Jun-20 30-Sep-19 30-Sep-20 30-Sep-19
Revenue 2,377.45 2,439.72 2,783.73 4,817.16 4,782.09EBITDA 988.50 1,178.47 1,309.31 2,166.97 2,358.44EBITDA Margin 41.58% 48.30% 47.03% 44.98% 49.32%EBIT 913.50 1,107.83 1,253.96 2,021.33 2,248.12EBIT Margin 38.42% 45.41% 45.05% 41.96% 47.01%Finance costs 32.63 32.06 39.91 64.69 74.33Depreciation 75.00 70.63 55.35 145.64 110.32Taxes 227.57 263.47 314.89 491.04 525.38Taxes to PBT 25.83% 24.49% 25.94% 25.10% 24.17%PAT (Standalone) 653.30 812.30 899.16 1,465.60 1,648.41PAT Margin (Standalone) 27.48% 33.29% 32.30% 30.42% 34.47%Unrealised Share of Profit of Associate Company 87.53 103.18 35.22 190.70 208.88PAT (Consolidated) 740.79 915.22 930.05 1,656.01 1,849.09PAT Margin (Consolidated) 31.16% 37.51% 33.41% 34.38% 38.67%EPS (Standalore) Per share 2.57 3.19 3.53 5.76 6.48EPS (Consolidated) 2.91 3.60 3.65 6.51 7.26Paid up share capital (Re.1/sh) 254.56 127.28 127.28 254.56 127.28
All figures are in INR Million, other than ratios and EPS13
Quarter ended Period ended
Company Background
14
Business Model
15
Contract Development
And Manufacturing
Operations (CDMO)
Process Research
Custom Synthesis
Formulation Development Analytical &
Services
Clinical Supplies Mfg& Packaging
Brief Profile
16
BUSINESS OVERVIEW
o Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing.
KEY STRENGTHS
o Preferred global outsourcing partner with capabilities across the entire CDMO value chain.
o Strong chemistry skills.
FINANCIAL OVERVIEW
o Revenues, EBITDA and Consolidated PAT of Rs 4817 Mn, Rs 2166 Mn and Rs 147 Mn in FH-FY21.
o Strong balance sheet with D:E ratio of 0.12 as on Mar-20.
Suven is an integrated Contract Development and Manufacturing Operations company
Suven Pharmaceuticals provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations.
Since our founding in 1989, Suven has established its core competency in cyanation and heterocyclic chemistry, including pyrimidines, quinolones, thiazoles, and imidazoles, in addition to demonstrating our proficiency in Carbohydrate and Chiral chemistry including tetrahydrofurans, amino acids and sulfoxides from gram to multi-ton scale.
Suven effectively uses its expanding infrastructure and ability to collaborate, from route scouting and development through commercial manufacture, to provide a consistent and reliable partner throughout a product's life cycle.
Suven is dedicated to going beyond commitment and delivering R&D and Manufacturing solutions, with flexibility, quality, speed, and cost effectiveness.
17
Our Focus
A full-fledged bio-pharmaceutical solutions provider for global pharmaceutical companies
18
NCE based CDMO
18
Financial Approach
19
Shareholder value creation
focus
Consistently dividend paying
Prudent utilisation of cash flows
Low debt
Business Drivers
20
State of the art facilities located across India and
US
Present across the entire CDMO value
chain –intermediates &
APIs
Leveraging on research capabilities to delivering NCE
research
An integrated research service provider with
unmatched capabilities
Business Drivers
21
Repeat business owing to long
standing relationships with MNC companies
Long term commercial supply opportunity with
the launch of product by global
sponsors
Working with innovator companies in developed markets
having stringent regulations –
reflection of our research skills
Over 90% of revenues from
regulated markets
Multi Location Facilities
Suryapet, Telangana, India
Intermediate Mfg. Facility
Banjara Hills, Hyderabad, India
Corporate Office
Pashamylaram, Telangana, India
API & Formulation Facility
Jeedimetla, Telangana, India
R&D–Pilot Plant
USA, New Jersey
Business Office
o Business Developmento Project Managemento Intellectual Property
Management
o Process Researcho Discovery R&D, Analytical R&Do Killo lab, 30L CM Reactors (32)o 50L – 4000 L GL/SS
o 300 CM reactors (93)o 500L to 10 KL GL/SSo GMP Intermediates
o 120 kL reaction volumeo 50L – 6000 L GL/SS (45)o API Manufacturing o Formulation R&D
o 307 KL reactor volumeo 3KL to 12KL Reactorso GL/SS (45No’s)o API’s/Advanced
Intermediate’s/CMO
Vizag, Andhra
Pradesh, India
22
Contact
Suven Pharmaceuticals Ltd
Email: [email protected]
For more info: www.suvenpharm.com
For queries and requests, please contact:
Gavin Desa / Rishab Barar
CDR - India
Tel: +91 22 6645 1237 / 1235
Email: [email protected]
Suven Pharmaceuticals Ltd# 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA.
+91-40-2354-9414 /1142 /3311
23
Thank You